These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

99 related items for PubMed ID: 11017135

  • 1. Specific immunotherapy: one size does not fit all.
    Genain CP, Zamvil SS.
    Nat Med; 2000 Oct; 6(10):1098-100. PubMed ID: 11017135
    [No Abstract] [Full Text] [Related]

  • 2. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand.
    Bielekova B, Goodwin B, Richert N, Cortese I, Kondo T, Afshar G, Gran B, Eaton J, Antel J, Frank JA, McFarland HF, Martin R.
    Nat Med; 2000 Oct; 6(10):1167-75. PubMed ID: 11017150
    [Abstract] [Full Text] [Related]

  • 3. Antigen-specific therapies in multiple sclerosis: going beyond proteins and peptides.
    Fontoura P, Garren H, Steinman L.
    Int Rev Immunol; 2005 Oct; 24(5-6):415-46. PubMed ID: 16318989
    [Abstract] [Full Text] [Related]

  • 4. Design and synthesis of a cyclic double mutant peptide (cyclo(87-99)[A91,A96]MBP87-99) induces altered responses in mice after conjugation to mannan: implications in the immunotherapy of multiple sclerosis.
    Katsara M, Deraos G, Tselios T, Matsoukas MT, Friligou I, Matsoukas J, Apostolopoulos V.
    J Med Chem; 2009 Jan 08; 52(1):214-8. PubMed ID: 19072222
    [Abstract] [Full Text] [Related]

  • 5. MBP-8298, a synthetic peptide analog of myelin basic protein for the treatment of multiple sclerosis.
    Darlington C.
    Curr Opin Mol Ther; 2007 Aug 08; 9(4):398-402. PubMed ID: 17694453
    [Abstract] [Full Text] [Related]

  • 6. [Copolymer 1 in therapy of multiple sclerosis].
    Weilbach FX, Voltz R, Hohlfeld R, Hartung HP.
    Nervenarzt; 1995 Jun 08; 66(6):473-7. PubMed ID: 7543660
    [No Abstract] [Full Text] [Related]

  • 7. T-cell vaccination in multiple sclerosis: immunoregulatory mechanism and prospects for therapy.
    Zhang J.
    Crit Rev Immunol; 2001 Jun 08; 21(1-3):41-55. PubMed ID: 11642613
    [Abstract] [Full Text] [Related]

  • 8. Latent TGF-beta1-transduced CD4+ T cells suppress the progression of allergic encephalomyelitis.
    Murano M, Xiong X, Murano N, Salzer JL, Lafaille JJ, Tsiagbe VK.
    J Leukoc Biol; 2006 Jan 08; 79(1):140-6. PubMed ID: 16244108
    [Abstract] [Full Text] [Related]

  • 9. Blood CD8+ T cell responses against myelin determinants in multiple sclerosis and healthy individuals.
    Berthelot L, Laplaud DA, Pettré S, Ballet C, Michel L, Hillion S, Braudeau C, Connan F, Lefrère F, Wiertlewski S, Guillet JG, Brouard S, Choppin J, Soulillou JP.
    Eur J Immunol; 2008 Jul 08; 38(7):1889-99. PubMed ID: 18506883
    [Abstract] [Full Text] [Related]

  • 10. Molecule of the month. Dirucotide.
    Drug News Perspect; 2008 Dec 08; 21(10):572. PubMed ID: 19221637
    [No Abstract] [Full Text] [Related]

  • 11. Myelin-basic protein-reactive specific CD4+ and CD8+ NK lymphocytes induce morphological changes in neuronal cell bodies and myelin sheaths: implications for multiple sclerosis.
    Zhang QY, Huang JH, Li HZ, Guo HT, Zhong YQ, Wang YM, Pei JM.
    Arch Med Res; 2008 Jan 08; 39(1):45-51. PubMed ID: 18067995
    [Abstract] [Full Text] [Related]

  • 12. Neuroimmunology of multiple sclerosis and experimental allergic encephalomyelitis.
    Stuerzebecher S, Martin R.
    Neuroimaging Clin N Am; 2000 Nov 08; 10(4):649-68 ,vii-viii. PubMed ID: 11359717
    [Abstract] [Full Text] [Related]

  • 13. Is there a place for 'immuno' in the immunotherapy of multiple sclerosis?
    Forsthuber TG, Muraro P.
    Immunotherapy; 2009 May 08; 1(3):329-31. PubMed ID: 20635950
    [No Abstract] [Full Text] [Related]

  • 14. Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease.
    Kidd P.
    Altern Med Rev; 2003 Aug 08; 8(3):223-46. PubMed ID: 12946237
    [Abstract] [Full Text] [Related]

  • 15. Future immunotherapies in multiple sclerosis.
    Blevins G, Martin R.
    Semin Neurol; 2003 Jun 08; 23(2):147-58. PubMed ID: 12894380
    [Abstract] [Full Text] [Related]

  • 16. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group.
    Kappos L, Comi G, Panitch H, Oger J, Antel J, Conlon P, Steinman L.
    Nat Med; 2000 Oct 08; 6(10):1176-82. PubMed ID: 11017151
    [Abstract] [Full Text] [Related]

  • 17. Degeneracy, as opposed to specificity, in immunotherapy.
    Hafler DA.
    J Clin Invest; 2002 Mar 08; 109(5):581-4. PubMed ID: 11877465
    [No Abstract] [Full Text] [Related]

  • 18. Immunopathogenesis and immunotherapeutic approaches in multiple sclerosis.
    Lim ET, Giovannoni G.
    Expert Rev Neurother; 2005 May 08; 5(3):379-90. PubMed ID: 15938671
    [Abstract] [Full Text] [Related]

  • 19. [Therapeutic strategy for multiple sclerosis targeting NK and NKT cells].
    Yamamura T.
    Rinsho Shinkeigaku; 2001 Dec 08; 41(12):1162-4. PubMed ID: 12235827
    [Abstract] [Full Text] [Related]

  • 20. Immunopathogenesis and immunotherapy of multiple sclerosis.
    Hemmer B, Nessler S, Zhou D, Kieseier B, Hartung HP.
    Nat Clin Pract Neurol; 2006 Apr 08; 2(4):201-11. PubMed ID: 16932551
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.